Cancers attributable to infectious agents in Italy.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
04 2023
Historique:
received: 10 11 2022
revised: 20 12 2022
accepted: 10 01 2023
pubmed: 22 2 2023
medline: 21 3 2023
entrez: 21 2 2023
Statut: ppublish

Résumé

To provide an evidence-based, comprehensive assessment of the current burden of infection-related cancers in Italy. We calculated the proportion of cancers attributable to infectious agents (Helicobacter pylori [Hp]; hepatitis B virus [HBV] and hepatitis C virus [HCV]; human papillomavirus [HPV]; human herpesvirus-8 [HHV8]; Epstein-Barr virus [EBV]; and human immunodeficiency virus [HIV]) to estimate the burden of infection-related cancer incidence (2020) and mortality (2017). Data on the prevalence of infections were derived from cross-sectional surveys of the Italian population, and relative risks from meta-analyses and large-scale studies. Attributable fractions were calculated based on the counterfactual scenario of a lack of infection. We estimated that 7.6% of total cancer deaths in 2017 were attributable to infections, with a higher proportion in men (8.1%) than in women (6.9%). The corresponding figures for incident cases were 6.5%, 6.9% and 6.1%. Hp was the first cause of infection-related cancer deaths (3.3% of the total), followed by HCV (1.8%), HIV (1.1%), HBV (0.9%), HPV, EBV and HHV8 (each ≤0.7%). Regarding incidence, 2.4% of the new cancer cases were due to Hp, 1.3% due to HCV, 1.2% due to HIV, 1.0% due to HPV, 0.6% due to HBV and <0.5% due to EBV and HHV8. Our estimate of 7.6% of cancer deaths and 6.9% of incident cases that were attributable to infections in Italy is higher than those estimated in other developed countries. Hp is the major cause of infection-related cancer in Italy. Prevention, screening and treatment policies are needed to control these cancers, which are largely avoidable.

Identifiants

pubmed: 36801622
pii: S0959-8049(23)00018-7
doi: 10.1016/j.ejca.2023.01.010
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-78

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Auteurs

Giulia Collatuzzo (G)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Carlo La Vecchia (C)

Department of Clinical Sciences and Community Health (DISCCO), University of Milan, 20122 Milan, Italy.

Fabio Parazzini (F)

Department of Clinical Sciences and Community Health (DISCCO), University of Milan, 20122 Milan, Italy; Department of Obstetrics, Gynecology, and Neonatology, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 12, 20122 Milan, Italy.

Gianfranco Alicandro (G)

Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy; Cystic Fibrosis Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Federica Turati (F)

Department of Clinical Sciences and Community Health (DISCCO), University of Milan, 20122 Milan, Italy.

Matteo Di Maso (M)

Department of Clinical Sciences and Community Health (DISCCO), University of Milan, 20122 Milan, Italy.

Matteo Malvezzi (M)

Department of Clinical Sciences and Community Health (DISCCO), University of Milan, 20122 Milan, Italy.

Claudio Pelucchi (C)

Department of Clinical Sciences and Community Health (DISCCO), University of Milan, 20122 Milan, Italy.

Eva Negri (E)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Department of Clinical Sciences and Community Health (DISCCO), University of Milan, 20122 Milan, Italy.

Paolo Boffetta (P)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA. Electronic address: paolo.boffetta@stonybrookmedicine.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH